keyword
MENU ▼
Read by QxMD icon Read
search

Vimpat

keyword
https://www.readbyqxmd.com/read/28427706/neuromyelitis-optica-spectrum-disorder-related-tonic-spasms-responsive-to-lacosamide
#1
A Baheerathan, W J Brownlee, F Rugg-Gunn, D T Chard, S A Trip
Paroxysmal tonic spasms [PTS] are common in patients with neuromyelitis optica spectrum disorder (NMOSD).1 2 In patients with demyelinating disease, PTS can significantly reduce the quality of life, limit activities of daily living and the rehabilitative process following an acute relapse 3. As in patients with multiple sclerosis (MS), paroxysmal tonic spasms in NMOSD usually respond well to treatment with carbamazepine.2 However, the optimal treatment in patients where carbamazepine is contraindicated or poorly tolerated is unclear...
April 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28005051/-russian-experience-of-lacosamide-vimpat-usage-in-treatment-of-uncontrolled-focal-epilepsy
#2
A V Lebedeva, S G Burd, O V Belyaev, P N Vlasov, M Yu Dorofeeva, A M Ismailov, M Ya Kissin, I Yu Kovaleva, N Yu Koroleva, L V Lipatova, K Yu Mukhin, Yu V Solomatin, A Chervyakov, R G Shikkherimov, O A Pylaeva, N V Freidkova
Many patients with epilepsy receive treatment in polytherapy. Selection of antiepileptic drugs (AEDs) for the combination should be carried out in accordance with the principles of rational polytherapy, taking into account the mechanism of action, pharmacokinetic (PK) and pharmacodynamic (PD) properties of drugs. Along with levetiracetam, gabapentin, vigabatrin and pregabalin, lacosamide (LCM) shows superior PK profile in rating of all AED and can be combined with any of them. The goal of this study was to evaluate efficacy and tolerability of LCM in patients with uncontrolled partial onset seizures (POS) in routine clinical practice...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/27917413/efficacy-of-s-lacosamide-in-preclinical-models-of-cephalic-pain
#3
Aubin Moutal, Nathan Eyde, Edwin Telemi, Ki Duk Park, Jennifer Y Xie, David W Dodick, Frank Porreca, Rajesh Khanna
Migraine is one of the world's most common neurological disorders. Current acute migraine treatments have sub-optimal efficacy and new therapeutic options are needed. Approaches targeting calcitonin gene related peptide (CGRP) signaling are clinically effective but small molecule antagonists have not been advanced due to toxicity. In this study, we explored the axonal growth/specification collapsin response mediator protein 2 (CRMP2) as a novel "druggable" target for inhibiting CGRP release and for potential relevance for treatment of migraine pain...
June 2016: Pain Reports (Baltimore, Md.)
https://www.readbyqxmd.com/read/27029451/-the-efficacy-of-intravenous-lacosamide-in-psychiatric-hospital
#4
I N Vakula, E O Bojko, U A Vorona, J A Storozhuk, E U Nikiforova, D I Nikiforova, T I Glazunova
OBJECTIVE: To evaluate the efficacy and tolerability of intravenous lacosamide (vimpat) in inpatients with frequent partial-onset seizures and affective and cognitive disorders. MATERIAL AND METHODS: Fifteen patients were enrolled including 14 patients diagnosed with «organic personality disorder associated with epilepsy» (cryptogenic or symptomatic epilepsy with frequent partial-onset and/or secondary-generalized seizures (serial seizures in some cases) and 1 patient with a preliminary diagnosis of «organic schizophrenia-like disorder», which was changed for «organic personality disorder associated with epilepsy» after examination...
2016: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/26967696/-s-lacosamide-inhibition-of-crmp2-phosphorylation-reduces-postoperative-and-neuropathic-pain-behaviors-through-distinct-classes-of-sensory-neurons-identified-by-constellation-pharmacology
#5
Aubin Moutal, Lindsey A Chew, Xiaofang Yang, Yue Wang, Seul Ki Yeon, Edwin Telemi, Seeneen Meroueh, Ki Duk Park, Raghuraman Shrinivasan, Kerry B Gilbraith, Chaoling Qu, Jennifer Y Xie, Amol Patwardhan, Todd W Vanderah, May Khanna, Frank Porreca, Rajesh Khanna
Chronic pain affects the life of millions of people. Current treatments have deleterious side effects. We have advanced a strategy for targeting protein interactions which regulate the N-type voltage-gated calcium (CaV2.2) channel as an alternative to direct channel block. Peptides uncoupling CaV2.2 interactions with the axonal collapsin response mediator protein 2 (CRMP2) were antinociceptive without effects on memory, depression, and reward/addiction. A search for small molecules that could recapitulate uncoupling of the CaV2...
July 2016: Pain
https://www.readbyqxmd.com/read/26607484/lacosamide-a-review-in-focal-seizures-in-patients-with-epilepsy
#6
REVIEW
Lesley J Scott
Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a solution or tablets) and as an intravenous infusion for use as monotherapy (only in the USA) or adjunctive therapy for the treatment of focal seizures in adult and adolescent (aged ≥17 years in the USA) patients with epilepsy. As adjunctive therapy to other antiepileptic drugs (AEDs), lacosamide provided effective seizure control and was generally well tolerated in adults and adolescents (aged ≥16 years) in randomized clinical trials and in the real-world setting...
December 2015: Drugs
https://www.readbyqxmd.com/read/25846820/-s-lacosamide-binding-to-collapsin-response-mediator-protein-2-crmp2-regulates-cav2-2-activity-by-subverting-its-phosphorylation-by-cdk5
#7
Aubin Moutal, Liberty François-Moutal, Samantha Perez-Miller, Karissa Cottier, Lindsey Anne Chew, Seul Ki Yeon, Jixun Dai, Ki Duk Park, May Khanna, Rajesh Khanna
The neuronal circuit remodels during development as well as in human neuropathologies such as epilepsy. Neurite outgrowth is an obligatory step in these events. We recently reported that alterations in the phosphorylation state of an axon specification/guidance protein, the collapsin response mediator protein 2 (CRMP2), play a major role in the activity-dependent regulation of neurite outgrowth. We also identified (S)-LCM, an inactive stereoisomer of the clinically used antiepileptic drug (R)-LCM (Vimpat®), as a novel tool for preferentially targeting CRMP2-mediated neurite outgrowth...
April 2016: Molecular Neurobiology
https://www.readbyqxmd.com/read/25104922/the-functionalized-amino-acid-s-lacosamide-subverts-crmp2-mediated-tubulin-polymerization-to-prevent-constitutive-and-activity-dependent-increase-in-neurite-outgrowth
#8
Sarah M Wilson, Aubin Moutal, Ohannes K Melemedjian, Yuying Wang, Weina Ju, Liberty François-Moutal, May Khanna, Rajesh Khanna
Activity-dependent neurite outgrowth is a highly complex, regulated process with important implications for neuronal circuit remodeling in development as well as in seizure-induced sprouting in epilepsy. Recent work has linked outgrowth to collapsin response mediator protein 2 (CRMP2), an intracellular phosphoprotein originally identified as axon guidance and growth cone collapse protein. The neurite outgrowth promoting function of CRMP2 is regulated by its phosphorylation state. In this study, depolarization (potassium chloride)-driven activity increased the level of active CRMP2 by decreasing its phosphorylation by GSK3β via a reduction in priming by Cdk5...
2014: Frontiers in Cellular Neuroscience
https://www.readbyqxmd.com/read/24944082/specific-binding-of-lacosamide-to-collapsin-response-mediator-protein-2-crmp2-and-direct-impairment-of-its-canonical-function-implications-for-the-therapeutic-potential-of-lacosamide
#9
REVIEW
Sarah M Wilson, Rajesh Khanna
The novel antiepileptic drug lacosamide (LCM; SPM927, Vimpat®) has been heralded as having a dual-mode of action through interactions with both the voltage-gated sodium channel and the neurite outgrowth-promoting collapsin response mediator protein 2 (CRMP2). Lacosamide's ability to dampen neuronal excitability through the voltage-gated sodium channel likely underlies its efficacy in attenuating the symptoms of epilepsy (i.e., seizures). While the role of CRMP2 in epilepsy has not been well studied, given the proposed involvement of circuit reorganization in epileptogenesis, the ability of lacosamide to alter CRMP2 function may prove disease modifying...
April 2015: Molecular Neurobiology
https://www.readbyqxmd.com/read/24636248/effect-of-lacosamide-on-structural-damage-and-functional-recovery-after-traumatic-brain-injury-in-rats
#10
A Pitkänen, R Immonen, X Ndode-Ekane, O Gröhn, T Stöhr, J Nissinen
In a subgroup of patients, traumatic brain injury (TBI) results in the occurrence of acute epileptic seizures or even status epilepticus, which are treated with antiepileptic drugs (AEDs). Recent experimental data, however, suggest that administration of AEDs at the early post-injury phase can compromise the recovery process. The present study was designed to assess the profile of a novel anticonvulsant, lacosamide (Vimpat) on post-TBI structural, motor and cognitive outcomes. Moderate TBI was induced by lateral fluid-percussion injury in adult rats...
May 2014: Epilepsy Research
https://www.readbyqxmd.com/read/24203890/lacosamide-a-review-of-its-use-as-adjunctive-therapy-in-the-management-of-partial-onset-seizures
#11
REVIEW
Sheridan M Hoy
Lacosamide (Vimpat(®)) is a functionalized amino acid available orally (as a syrup or tablet) and as an intravenous infusion. It is believed to exert its antiepileptic effect by selectively enhancing the slow inactivation of voltage-gated sodium channels. Lacosamide is approved in several countries worldwide as an adjunctive therapy for the treatment of partial-onset seizures; however, prescribing regulations differ between countries. This article reviews the use of lacosamide as indicated in adults and adolescents (aged 16-18 years) in the EU, where it is approved in this patient population as an adjunctive therapy to other AEDs in the treatment of partial-onset seizures, with or without secondary generalization...
December 2013: CNS Drugs
https://www.readbyqxmd.com/read/23750855/synergism-of-lacosamide-with-established-antiepileptic-drugs-in-the-6-hz-seizure-model-in-mice
#12
Alexey Shandra, Pavel Shandra, Olga Kaschenko, Alain Matagne, Thomas Stöhr
PURPOSE: Lacosamide (LCM, Vimpat) is an anticonvulsant with a unique mode of action. This provides lacosamide with the potential to act additively or even synergistically with other antiepileptic drugs (AEDs). The objective of this study was to determine the presence of such interactions by isobolographic analysis. METHODS: The anticonvulsant effect of LCM in combination with other AEDs including carbamazepine (CBZ), phenytoin (PHT), valproate (VPA), lamotrigine (LTG), topiramate (TPM), gabapentin (GBP), and levetiracetam (LEV) at fixed dose ratios of 1:3, 1:1, and 3:1, was evaluated in the 6-Hz-induced seizure model in mice...
July 2013: Epilepsia
https://www.readbyqxmd.com/read/23193979/efficacy-and-tolerability-of-lacosamide-in-the-concomitant-treatment-of-130-patients-under-16-years-of-age-with-refractory-epilepsy-a-prospective-open-label-observational-multicenter-study-in-spain
#13
MULTICENTER STUDY
Carlos Casas-Fernández, Antonio Martínez-Bermejo, Miguel Rufo-Campos, Patricia Smeyers-Durá, José L Herranz-Fernández, Salvador Ibáñez-Micó, Jaume Campistol-Plana, Helena Alarcón-Martínez, Jaime Campos-Castelló
BACKGROUND: The safety and effectiveness of lacosamide, an antiepileptic drug (AED) that selectively enhances the slow inactivation of voltage-gated sodium channels without affecting rapid inactivation, has been demonstrated in randomized, double-blind, placebo-controlled trials in adults with focal epileptic seizures. Although lacosamide is approved for use in patients over 16 years of age, limited clinical experience exists for younger patients. OBJECTIVE: To assess the efficacy and tolerability of lacosamide in children with refractory epilepsy...
December 1, 2012: Drugs in R&D
https://www.readbyqxmd.com/read/22983249/-lacosamide-in-the-treatment-of-epilepsy
#14
REVIEW
A S Petrukhin, K V Voronkova, O A Pylaeva
The new antiepileptic drug (AED) lacosamide (vimpat, "UCB Pharma") with a new mechanism of action was registered in Russia in 2010. The drug should be used as add-on treatment in patients over 16 years and older with non-controlled focal seizures with- or without secondary localization. The authors review the data of literature and the results of trials on efficacy and safety of lacosamide for peroral and intravenous introduction. Randomized clinical trials of the peroral form of this drug provide evidence that lacosamide is a prospective preparation for complex treatment of drug-resistant epilepsy in the view of its safety and tolerability...
2012: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/22672303/drug-binding-assays-do-not-reveal-specific-binding-of-lacosamide-to-collapsin-response-mediator-protein-2-crmp-2
#15
Christian Wolff, Bruce Carrington, Michel Varrin-Doyer, Anne Vandendriessche, Christy Van der Perren, Michel Famelart, Michel Gillard, Patrik Foerch, Véronique Rogemond, Jerôme Honnorat, Alastair Lawson, Karen Miller
AIMS: Lacosamide (LCM; SPM 927, Vimpat®) is an antiepileptic drug (AED) used as adjunctive treatment for adults with partial-onset seizures. LCM has a different mode of action from traditional sodium channel blocking AEDs in that it selectively enhances slow inactivation of sodium channels without affecting fast inactivation. Initial investigations suggested that LCM might have an additional mode of action by binding to the collapsin response mediator protein 2 (CRMP-2), which is further investigated here...
June 2012: CNS Neuroscience & Therapeutics
https://www.readbyqxmd.com/read/22122600/a-simple-hplc-uv-method-for-the-determination-of-lacosamide-in-human-plasma
#16
C Kestelyn, M Lastelle, N Higuet, S Dell'Aiera, L Staelens, P Boulanger, H Boekens, S Smith
Lacosamide (Vimpat®) is an antiepileptic drug approved in the USA, Europe and several other countries as adjunctive therapy for partial-onset seizures. We report a simple HPLC method with UV detection for the quantification of lacosamide in human plasma. The method involves protein precipitation with methanol followed by chromatographic separation using an ACE® C18-AR column (2.1 mm × 150 mm, 3.0 µm) and mobile phases consisting of mixtures of ammonium formate buffer at pH 9 and acetonitrile. Briefly, 25 µl of internal standard and 300 µl of methanol are added to 100 µl of plasma...
November 2011: Bioanalysis
https://www.readbyqxmd.com/read/21532923/development-and-characterization-of-novel-derivatives-of-the-antiepileptic-drug-lacosamide-that-exhibit-far-greater-enhancement-in-slow-inactivation-of-voltage-gated-sodium-channels
#17
Yuying Wang, Ki Duk Park, Christophe Salome, Sarah M Wilson, James P Stables, Rihe Liu, Rajesh Khanna, Harold Kohn
The novel antiepileptic drug, (R)-N-benzyl 2-acetamido-3-methoxypropionamide ((R)-lacosamide, Vimpat(®) ((R)-1)), was recently approved in the US and Europe for adjuvant treatment of partial-onset seizures in adults. (R)-1 preferentially enhances slow inactivation of voltage-gated Na(+) currents, a pharmacological process relevant in the hyperexcitable neuron. We have advanced a strategy to identify lacosamide binding partners by attaching affinity bait (AB) and chemical reporter (CR) groups to (R)-1 to aid receptor detection and isolation...
February 16, 2011: ACS Chemical Neuroscience
https://www.readbyqxmd.com/read/21510453/-antiepileptic-drug-lacosamide-vimpat
#18
REVIEW
L R Zenkov
No abstract text is available yet for this article.
2010: Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova
https://www.readbyqxmd.com/read/21473129/-lacosamide-oral-administration-vimpat
#19
Daniel Duh, Sandrine Peeters
No abstract text is available yet for this article.
March 2011: Journal de Pharmacie de Belgique
https://www.readbyqxmd.com/read/21090839/a-pooled-analysis-of-lacosamide-clinical-trial-data-grouped-by-mechanism-of-action-of-concomitant-antiepileptic-drugs
#20
John-Kenneth Sake, David Hebert, Jouko Isojärvi, Pamela Doty, Marc De Backer, Kendra Davies, Andrea Eggert-Formella, James Zackheim
BACKGROUND: Lacosamide, a new antiepileptic drug (AED) with a different pharmacological action that enhances sodium channel slow inactivation, is approved for the adjunctive treatment of partial-onset seizures in adults. Previous analyses of pooled phase II/III trials have demonstrated that lacosamide provides additional efficacy when added to a broad range of AEDs. OBJECTIVE: To further evaluate the efficacy and safety of lacosamide by grouping patients based upon the sodium channel-blocking properties of their concomitant AEDs...
December 2010: CNS Drugs
keyword
keyword
41756
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"